Torq Announces 300% Revenue Growth and 200% Employee Growth as Torq’s AI-Powered SOC and Agentic AI Security Solutions Achieve Fortune 500 Customer Traction
28.1.2025 15:00:00 CET | Business Wire | Press Release
Torq, the autonomous security operations leader, today announced that in 2024, it achieved 300% revenue growth and 200% employee growth. Torq is also expanding operations across EMEA, opening new EMEA headquarters in London, and appointing Usman Gulfaraz as its new VP of EMEA Sales. Torq’s EMEA momentum mirrors the tremendous growth it experienced in 2024 across North and South America, and APAC, where Torq HyperSOC and Torq Hyperautomation products are now firmly established as the premiere Agentic AI and autonomous SOC solutions of choice for the Fortune 500. These announcements follow Torq’s recent closing of its $70M Series C round, which brought its total funding to $192M. For 2026, Torq has established an aggressive ARR target of $100M, which includes EMEA revenue.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250128254651/en/
Torq's EMEA Headquarters in London (Photo: Business Wire)
Gulfaraz is a revered sales veteran who was most recently responsible for global revenue at Speechmatics. Previously, he ran EMEA for Tessian, which he helped lead to acquisition by Proofpoint. Prior to that, he ran EMEA for Shape Security which he helped lead to acquisition by F5. Torq has also appointed Jaicee Matthews as its Head of EMEA Marketing. Matthews previously led marketing teams for GTT, Edgio, and Lumen Technologies. Gulfarez and Matthews are based in Torq’s new London headquarters. Sheldon Muir, Head of Global Channels and Alliances, is managing the EMEA partner ecosystem from Torq’s New York City worldwide headquarters.
“We’re seeing extraordinary enterprise demand for Torq’s Agentic AI security solutions across EMEA,” said Gulfaraz. “Organizations understand the incredible results Torq is delivering for multinational companies. They’ve seen how our technology transformed the cybersecurity landscape during 2024, with the introduction of the expanded Torq HyperSOC featuring our Agentic AI Multi-Agent Framework. And now they’re eager to deploy these solutions to enhance their own security operations. Torq officially brought the SOAR era to a close last year. In 2025, the sky’s the limit for Torq as it continues to rapidly evolve into a global force.”
Torq’s customer base includes some of the biggest names in cybersecurity, consumer packaged goods, industrial automation, online services, retail, and telecommunications, such as Check Point Security, Chipotle Mexican Grill, Inditex (Zara, Bershka, and Pull & Bear), Informatica, PepsiCo, Procter & Gamble, Siemens, Telefonica, Wiz, and World Economic Forum.
“Today, Torq HyperSOC investigates, triages, and remediates many of Check Point’s internal security alerts without any human intervention,” said Jonathan Fischbein CISO, Check Point. “If an alert meets certain parameters based on organizational security policies, the platform takes relevant predefined steps, such as initiating an MFA challenge or locking out a suspicious user. We can react automatically to problems before they become security incidents.”
Torq’s ever-expanding EMEA partner base includes AdvanceSec, Bytes Software Services, Check Point, GlobalDots, Nubera, Nueva Group, Softcat, Tata Group, Wiz, and WWT.
“We are thrilled to partner with Torq and continue to deliver innovation that matters to our customers,” said Adam McCaig, Head of Security Strategy and Services, Bytes Software Services. “Demand for Torq’s game-changing Hyperautomation Platform and Torq HyperSOC continues expanding exponentially. Together, Torq and Bytes Software Services are making enterprise SecOps teams across EMEA more productive and focused with their AI-driven SecOps and autonomous SOC solutions, ensuring organizations can mitigate existential security issues before they have a chance of creating adverse impacts.”
Learn more about Torq at Torq.io.
About Torq
Torq is transforming cybersecurity with its agentic AI security operations solutions. Torq empowers enterprises to instantly and precisely detect and respond to security events at scale. Fortune 500 companies, including the world’s biggest financial, technology, consumer packaged goods, fashion, hospitality, and sports apparel organizations are experiencing extraordinary outcomes with Torq.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128254651/en/
Contacts
Media Contact:
Tiana Petricevic
torq@highwirepr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom